Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin

Annals of Surgical Oncology

Volumn 21, Issue 5, 2014, Pages 1456-1462

  Winer, Joshua ^a   Zenati, Mazen ^b   Ramalingam, Lekshmi ^a   Jones, Heather ^a   Zureikat, Amer ^a   Holtzman, Matthew ^a   Lee, Kenneth ^a   Ahrendt, Steven ^a   Pingpank, James ^a   Zeh, Herbert J ^a   Bartlett, David L ^a   Choudry, Haroon A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLEEDING; BODY MASS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOSIS; CARCINOMATOUS PERITONITIS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOPERFUSION; HYPERTHERMIC THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; OUTCOME ASSESSMENT; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; SIGNET RING CARCINOMA; THERAPY EFFECT; APPENDICEAL NEOPLASMS; CANCER STAGING; CARCINOMA, SIGNET RING CELL; COLORECTAL NEOPLASMS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDY; REGIONAL PERFUSION; SECONDARY; SURVIVAL RATE;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APPENDICEAL NEOPLASMS; CARCINOMA, SIGNET RING CELL; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTHERMIA, INDUCED; MALE; MIDDLE AGED; NEOPLASM STAGING; PERITONEAL NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84898861726     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3328-4     Document Type: Article

References (36)

1. Hyngstrom JR, Hu CY, Xing Y, You YN, Feig BW, Skibber JM, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: Analysis from the National Cancer Data Base. Ann Surg Oncol. 2012;19:2814-2821.
2. Chua TC, Pelz JO, Kerscher A, Morris DL, Esquivel J. Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma. Ann Surg Oncol. 2009;16:2765-2770.
3. Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol. 2012;19:1379-1385.
4. Kang H, O'Connell JB, Maggard MA, Sack J, Ko CY. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis Colon Rectum. 2005;48:1161-1168. (Pubitemid 40897859)
5. Ko YH, Jung CK, Oh SN, Kim TH, Won HS, Kang JH, et al. Primary signet ring cell carcinoma of the appendix: A rare case report and our 18-year experience. World J Gastroenterol. 2008;14:5763-5768.
6. McGory ML, Maggard MA, Kang H, O'Connell JB, Ko CY. Malignancies of the appendix: beyond case series reports. Dis Colon Rectum. 2005;48:2264-2271. (Pubitemid 43074447)
7. Psathakis D, Schiedeck TH, Krug F, Oevermann E, Kujath P, Bruch HP. Ordinary colorectal adenocarcinoma vs primary colorectal signet-ring cell carcinoma: study matched for age, gender, grade, and stage. Dis Colon Rectum. 1999;42:1618-1625. (Pubitemid 30007599)
8. Mizushima T, Nomura M, Fujii M, Akamatsu H, Mizuno H, Tominaga H, et al. Primary colorectal signet-ring cell carcinoma: clinicopathological features and postoperative survival. Surg Today. 2010;40:234-238.
9. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-3743. (Pubitemid 46606227)
10. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426-2432.
11. Makino T, Tsujinaka T, Mishima H, Ikenaga M, Sawamura T, Nakamori S, et al. Primary signet-ring cell carcinoma of the colon and rectum: report of eight cases and review of 154 Japanese cases. Hepatogastroenterology. 2006;53:845-849. (Pubitemid 44851213)
12. Sasaki S, Masaki T, Umetani N, Futakawa N, Ando H, Muto T. Characteristics in primary signet-ring cell carcinoma of the colorectum, from clinicopathological observations. Jpn J Clin Oncol. 1998;28:202-206. (Pubitemid 128525570)
13. Tung SY, Wu CS, Chen PC. Primary signet ring cell carcinoma of colorectum: An age- and sex-matched controlled study. Am J Gastroenterol. 1996;91:2195-2199.
14. Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, et al. Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum. 2008;51:50-55.
15. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-363. (Pubitemid 30051820)
16. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263-267.
17. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ III. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer. 2010;116:3756-3762.
18. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681-685.
19. Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: A multicenter study. Ann Surg Oncol. 2011;18:1560-1567.
20. Mahteme H, Hansson J, Berglund A, Påhlman L, Glimelius B, Nygren P, et al. Improved survival in patients with peritoneal metastases from colorectal cancer: A preliminary study. Br J Cancer. 2004;90:403-407. (Pubitemid 38250636)
21. Farquharson AL, Pranesh N, Witham G, Swindell R, Taylor MB, Renehan AG, et al. A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei. Br J Cancer. 2008;99:591-596.
22. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol. 2004;22:3284-3292. (Pubitemid 41103684)
23. Borger ME, Gosens MJ, Jeuken JW, van Kempen LC, van de Velde CJ, van Krieken JH, et al. Signet ring cell differentiation in mucinous colorectal carcinoma. J Pathol. 2007;212:278-286. (Pubitemid 47010061)
24. Sung CO, Seo JW, Kim KM, Do IG, Kim SW, Park CK. Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma. Mod Pathol. 2008;21:1533-1541.
25. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-374.
26. Bao P, Bartlett D. Surgical techniques in visceral resection and peritonectomy procedures. Cancer J. 2009;15:204-211.
27. Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, et al. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol. 2008;15:754-763.
28. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213. (Pubitemid 38963009)
29. Austin F, Mavanur A, Sathaiah M, Steel J, Lenzner D, Ramalingam L, et al. Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol. 2012;19:1386-1393.
30. Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484-492. (Pubitemid 46175292)
31. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102:576-581.
32. Bijelic L, Kumar AS, Stuart OA, Sugarbaker PH. Systemic chemotherapy prior to cytoreductive surgery and HIPEC for carcinomatosis from appendix cancer: impact on perioperative outcomes and short-term survival. Gastroenterol Res Pract. 2012;2012:163284.
33. Sammartino P, Sibio S, Biacchi D, Cardi M, Accarpio F, Mingazzini P, et al. Prevention of peritoneal metastases from colon cancer in high-risk patients: preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract. 2012;2012:141585.
34. Gopalan V, Smith RA, Ho YH, Lam AK. Signet-ring cell carcinoma of colorectum - current perspectives and molecular biology. Int J Colorectal Dis. 2011;26:127-133.
35. Kakar S, Deng G, Smyrk TC, Cun L, Sahai V, Kim YS. Loss of heterozygosity, aberrant methylation, BRAF mutation and KRAS mutation in colorectal signet ring cell carcinoma. Mod Pathol. 2012;25:1040-1047.
36. Wang K, Weinrach D, Lal A, Musunuri S, Ramirez J, Ozer O, et al. Signet-ring cell change versus signet-ring cell carcinoma: A comparative analysis. Am J Surg Pathol. 2003;27:1429-1433. (Pubitemid 37315194)